QuidelOrtho Corporation is positioned for growth driven by its diversified product portfolio and cost-saving initiatives, despite mixed first-quarter 2026 results and ongoing respiratory testing headwinds. The company's Labs segment generated $353.1 million in revenue, leading a portfolio that also includes Immunohematology at $138.3 million and Point of Care at $112.8 million, while the U.S. launch of a high-sensitivity troponin assay has already reached more than 300 customer shipments. QuidelOrtho is targeting approximately $50 million in net cost savings through 2027 via its Optimization Plan, even as it faces cumulative pre-tax charges of about $100 million, and reaffirmed a full-year adjusted EBITDA margin target of approximately 23%. However, first-quarter respiratory revenues fell to $68 million amid a roughly 30% year-over-year decline in influenza-like illness visits, contributing to a 630-basis point drop in adjusted gross margin, and the Zacks Consensus Estimate for 2026 earnings has moved down to $1.87 per share over the past 30 days.
Quidel CorporationCost-saving initiatives and reaffirmed EBITDA margin target offset respiratory weakness.
West Pharmaceutical Services Inc
Cardinal Health Inc
Intuitive Surgical Inc